We also allowed for separate ovarian cancer relative risks in the age groups 30–49, 50–59, and 60–69 years for BRCA1 and in the age groups 30–49 and 50–69 years for BRCA2. This evidence concerns the gene BRCA2 and ovarian carcinoma.